See more : PlantX Life Inc. (VEGA.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Tectonic Therapeutic Inc (TECX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tectonic Therapeutic Inc, a leading company in the None industry within the None sector.
You may be interested
- Xylo Technologies Ltd. (XYLO) Income Statement Analysis – Financial Results
- Scorpio Gold Corporation (SGN.V) Income Statement Analysis – Financial Results
- National Express Group PLC (NEX.L) Income Statement Analysis – Financial Results
- FibraHotel (FIHO12.MX) Income Statement Analysis – Financial Results
- Fresh Del Monte Produce Inc. (FDP) Income Statement Analysis – Financial Results
Tectonic Therapeutic Inc (TECX)
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 617.00K | 4.17M | 1.40M | 1.21M | 850.00K | 380.00K | 45.00K | 0.00 |
| Gross Profit | -617.00K | -4.17M | -1.40M | -1.21M | -850.00K | -380.00K | -45.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 36.97M | 68.02M | 81.72M | 86.03M | 54.97M | 35.10M | 15.19M | 2.66M |
| General & Administrative | 7.68M | 7.18M | 4.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 26.07M | 31.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.68M | 33.25M | 35.73M | 32.99M | 19.99M | 10.77M | 3.15M | 1.96M |
| Other Expenses | 0.00 | 2.00K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 44.65M | 101.27M | 117.44M | 119.02M | 74.96M | 45.86M | 18.34M | 4.63M |
| Cost & Expenses | 44.65M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Interest Income | 2.42M | 149.00K | 0.00 | 719.00K | 2.93M | 1.73M | 57.00K | 6.00K |
| Interest Expense | 0.00 | 144.00K | 445.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.48M | 4.17M | 1.40M | 1.21M | 850.00K | 380.00K | 45.00K | 0.00 |
| EBITDA | -43.17M | -101.43M | -117.50M | -118.51M | -72.12M | -45.98M | -18.60M | -4.66M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -44.65M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.39M | -4.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.83M | -73.06M | -103.52M | 516.00K | 2.84M | -118.00K | -262.00K | -39.00K |
| Income Before Tax | -42.82M | -105.89M | -119.13M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 377.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -42.82M | -105.89M | -119.13M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -11.59 | -29.05 | -33.36 | -39.68 | -31.92 | -41.41 | -9.35 | -2.34 |
| EPS Diluted | -11.53 | -29.05 | -33.36 | -39.68 | -31.92 | -41.41 | -9.35 | -2.34 |
| Weighted Avg Shares Out | 3.69M | 3.64M | 3.57M | 3.02M | 2.29M | 1.12M | 1.99M | 1.99M |
| Weighted Avg Shares Out (Dil) | 3.71M | 3.64M | 3.57M | 3.02M | 2.29M | 1.12M | 1.99M | 1.99M |
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today...
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today...
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced...
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
American Heart Association (AHA) poster to be presented on November 16, 2024 American Heart Association (AHA) poster to be presented on November 16, 2024
Tectonic Therapeutic: Interesting CV Disease Drug Developer
Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and...
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial
TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024
Tectonic Therapeutic (NASDAQ: TECX ) just reported results for the second quarter of 2024. Tectonic Therapeutic reported earnings per share of -$4.34.
Tectonic Therapeutic to Participate in September Investor Conferences
WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today...
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024 Completed reverse merger...
Source: https://incomestatements.info
Category: Stock Reports